KKR’s 51.8% Premium for Integer Is Measured From Before the Company Said It Was for Sale
KKR’s 51.8% premium for Integer is struck to the day before Integer said it was for sale. The 28.8% is what a holder actually gained.
Topics
Indivior’s Holders Take 56.5% and $1 Billion, Supernus Takes the Name, the CEO and the Building
Indivior holders take 56.5% and a billion in cash. Supernus takes the name, the CEO and the building. Equals describes the board seats only.
Curium’s CVR Waterfall Says It Trusts DEFINITY, Is Betting on Neurology, and Doubts Prostate
Curium locked 89.5% of consideration in cash and hung the rest on prostate. The CVR waterfall is the buyer’s own forecast, published.
Congress Exempted the Medically Frail. The Coding System Cannot Find Them.
Fewer than 500 of 10,000 rare diseases have an ICD-10 code. The Medicaid frailty exemption is verified against codes most patients never had.
An FDA Panel Voted 9-3 Against Capricor on Cardiomyopathy and Never Voted on the Endpoint That Passed
The ballot was the outcome. A drug’s strongest dataset sitting off the voting question is not a footnote, it is the whole result.
Revtorpyk Got Its NCCN Category 1 Listing Two Months Before Celcuity Can Sell a Single Vial
The reimbursement case is being built before the product exists. Two gates remain, and a guideline solves neither.
NICE Backed Aficamten the Same Day the MHRA Authorised It, at a Price It Will Not Disclose
Concurrent MHRA and NICE decisions collapse the usual access gap to zero. Then read the conditions, because that is where the guidance lives.
J&J Paid $785 Million for a Look at Something That Has Never Been in a Human
J&J committed $785 million including a $465 million equity stake, plus an option to acquire Sail Biomedicines for $2.58 billion, on a preclinical in vivo CAR-T platform.
The Biosimilar Was Too Cheap to Sell. So the Price Went Up Fourfold.
Byooviz relaunched in the US at an average sales price of $1,190, roughly four times its previous level and above the originator it references.
Washington Removed the Cushion Under Part D, and Handed the Auditors an Algorithm
Washington ended the subsidy holding Part D premiums down, charged a record number of Medicaid fraud defendants, and put prosecutors’ analytics inside CMS.